Valley National Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $680K | Sell |
1,091
-96
| -8% | -$65.3K | 0.08% | 156 |
|
|
2026
Q1 | $917K | Sell |
1,187
-16
| -1% | -$12.2K | 0.12% | 140 |
|
|
2025
Q4 | $928K | Buy |
1,203
+110
| +10% | +$74.7K | 0.13% | 137 |
|
|
2025
Q3 | $614K | Sell |
1,093
-280
| -20% | -$158K | 0.1% | 155 |
|
|
2025
Q2 | $720K | Buy |
1,373
+2
| +0.1% | +$1.12K | 0.12% | 146 |
|
|
2025
Q1 | $869K | Buy |
1,371
+132
| +11% | +$90.8K | 0.16% | 133 |
|
|
2024
Q4 | $882K | Sell |
1,239
-41
| -3% | -$34.4K | 0.16% | 128 |
|
|
2024
Q3 | $1.34M | Sell |
1,280
-168
| -12% | -$187K | 0.24% | 112 |
|
|
2024
Q2 | $1.52M | Sell |
1,448
-5
| -0.3% | -$4.85K | 0.23% | 91 |
|
|
2024
Q1 | $1.4M | Buy |
1,453
+59
| +4% | +$56.1K | 0.21% | 93 |
|
|
2023
Q4 | $1.22M | Buy |
1,394
+24
| +2% | +$19.8K | 0.19% | 98 |
|
|
2023
Q3 | $1.13M | Buy |
1,370
+34
| +3% | +$26.7K | 0.2% | 94 |
|
|
2023
Q2 | $961K | Sell |
1,336
-2
| -0.1% | -$1.54K | 0.16% | 111 |
|
|
2023
Q1 | $1.07M | Sell |
1,338
-14
| -1% | -$10.6K | 0.19% | 103 |
|
|
2022
Q4 | $959K | Sell |
1,352
-13
| -1% | -$9.59K | 0.17% | 108 |
|
|
2022
Q3 | $986K | Buy |
1,365
+51
| +4% | +$32.1K | 0.21% | 100 |
|
|
2022
Q2 | $798K | Buy |
1,314
+29
| +2% | +$18.9K | 0.17% | 107 |
|
|
2022
Q1 | $898K | Buy |
1,285
+35
| +3% | +$22.1K | 0.17% | 123 |
|
|
2021
Q4 | $789K | Buy |
1,250
+2
| +0.2% | +$1.23K | 0.15% | 136 |
|
|
2021
Q3 | $755K | Buy |
1,248
+145
| +13% | +$90K | 0.14% | 130 |
|
|
2021
Q2 | $616K | Buy |
1,103
+471
| +75% | +$239K | 0.11% | 143 |
|
|
2021
Q1 | $299K | Buy |
632
+13
| +2% | +$6.33K | 0.06% | 184 |
|
|
2020
Q4 | $299K | Buy |
619
+152
| +33% | +$82K | 0.06% | 177 |
|
|
2020
Q3 | $261K | Buy |
467
+87
| +23% | +$52.8K | 0.06% | 162 |
|
|
2020
Q2 | $237K | Buy |
380
+136
| +56% | +$77.2K | 0.05% | 174 |
|
|
2020
Q1 | $119K | Sell |
244
-265
| -52% | -$109K | 0.03% | 201 |
|
|
2019
Q4 | $191K | Hold |
509
| – | – | 0.05% | 201 |
|
|
2019
Q3 | $141K | Buy |
509
+10
| +2% | +$2.96K | 0.04% | 213 |
|
|
2019
Q2 | $156K | Buy |
499
+159
| +47% | +$52.9K | 0.04% | 197 |
|
|
2019
Q1 | $140K | Sell |
340
-159
| -32% | -$65.5K | 0.04% | 198 |
|
|
2018
Q4 | $186K | Buy |
499
+9
| +2% | +$3.29K | 0.06% | 168 |
|
|
2018
Q3 | $198K | Hold |
490
| – | – | 0.07% | 167 |
|
|
2018
Q2 | $169K | Buy |
490
+59
| +14% | +$18.5K | 0.06% | 176 |
|
|
2018
Q1 | $148K | Buy |
431
+80
| +23% | +$27.8K | 0.06% | 179 |
|
|
2017
Q4 | $132K | Sell |
351
-9
| -3% | -$3.65K | 0.05% | 185 |
|
|
2017
Q3 | $161K | Buy |
360
+345
| +2,300% | +$164K | 0.06% | 166 |
|
|
2017
Q2 | $7K | Hold |
15
| – | – | ﹤0.01% | 445 |
|
|
2017
Q1 | $6K | Hold |
15
| – | – | ﹤0.01% | 465 |
|
|
2016
Q4 | $6K | Hold |
15
| – | – | ﹤0.01% | 467 |
|
|
2016
Q3 | $6K | Hold |
15
| – | – | ﹤0.01% | 440 |
|
|
2016
Q2 | $5K | Hold |
15
| – | – | ﹤0.01% | 455 |
|
|
2016
Q1 | $5K | Hold |
15
| – | – | ﹤0.01% | 446 |
|
|
2015
Q4 | $8K | Sell |
15
-19
| -56% | -$10.3K | ﹤0.01% | 405 |
|
|
2015
Q3 | $16K | Hold |
34
| – | – | 0.01% | 321 |
|
|
2015
Q2 | $17K | Hold |
34
| – | – | 0.01% | 321 |
|
|
2015
Q1 | $15K | Buy |
+34
| New | +$14.4K | 0.01% | 333 |
|
Other funds holding REGN
Valley National Advisers's REGN Position: Q2 2026 in Review
Valley National Advisers reduced its Regeneron Pharmaceuticals (REGN) stake by 8.1% in Q2 2026, selling an estimated $65.3K and leaving 1,091 shares worth $680K. The position accounts for 0.08% of the portfolio, ranked #156.
Valley National Advisers first reported a position in REGN in Q1 2015 and has held it in 46 quarters since. The position peaked at $1.52M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Valley National Advisers held 1,091 shares of Regeneron Pharmaceuticals worth $680K as of Q2 2026.
- Valley National Advisers sold 96 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $65.3K.
- Regeneron Pharmaceuticals made up 0.08% of Valley National Advisers's portfolio in Q2 2026, its #156 holding.
- Valley National Advisers first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 46 quarters since.
- Valley National Advisers's Regeneron Pharmaceuticals position peaked at $1.52M in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.